ForeSENTIA: Gene-Focused PIK3CA & AKT1
ForeSENTIA PIK3CA and AKT1 Gene-Focused Panel tests for single nucleotide variants, insertions and deletions on the PIK3CA and AKT1 genes. PIK3CA and AKT1 are two genes that transcribe two separate protein kinases, PI3K and AKT1 respectively. Both proteins belong to the PI3K/AKT pathway and play an essential role in regulating different signalling pathways and processes in the cells, such as cell division and survival.
In cancer, these genes can be mutated leading to aberrant activation of the PI3K/AKT pathway. As a result, this will cause an increase in cell proliferation and cancer progression. Some examples of cancers caused as a result include colorectal, breast, prostate, NSCLC, and others.
Different drugs against PIK3CA and AKT1 are currently being studied for their efficacy in different types of tumours. One drug that was approved by FDA and EMA, alpelisib, targets PIK3CA mutations in patients with breast cancer.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?


Certified laboratories

